PL3082956T3 - Inhibitor punktu kontrolnego i mycobacterium całokomórkowe do stosowania w terapii raka - Google Patents
Inhibitor punktu kontrolnego i mycobacterium całokomórkowe do stosowania w terapii rakaInfo
- Publication number
- PL3082956T3 PL3082956T3 PL14827518T PL14827518T PL3082956T3 PL 3082956 T3 PL3082956 T3 PL 3082956T3 PL 14827518 T PL14827518 T PL 14827518T PL 14827518 T PL14827518 T PL 14827518T PL 3082956 T3 PL3082956 T3 PL 3082956T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer therapy
- whole cell
- checkpoint inhibitor
- cell mycobacterium
- mycobacterium
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 241000186359 Mycobacterium Species 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1322725.1A GB201322725D0 (en) | 2013-12-20 | 2013-12-20 | Cancer therapy |
EP14827518.3A EP3082956B1 (en) | 2013-12-20 | 2014-12-16 | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
PCT/GB2014/053717 WO2015092382A1 (en) | 2013-12-20 | 2014-12-16 | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3082956T3 true PL3082956T3 (pl) | 2022-05-23 |
Family
ID=50071260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14827518T PL3082956T3 (pl) | 2013-12-20 | 2014-12-16 | Inhibitor punktu kontrolnego i mycobacterium całokomórkowe do stosowania w terapii raka |
Country Status (18)
Country | Link |
---|---|
US (7) | US10610577B2 (pl) |
EP (1) | EP3082956B1 (pl) |
JP (2) | JP6858558B2 (pl) |
KR (1) | KR101820393B1 (pl) |
CN (2) | CN111671908A (pl) |
AU (2) | AU2014369510B2 (pl) |
BR (1) | BR112016013887B1 (pl) |
CA (1) | CA2932659C (pl) |
ES (1) | ES2913460T3 (pl) |
GB (1) | GB201322725D0 (pl) |
IL (1) | IL246083B2 (pl) |
MX (1) | MX2016007709A (pl) |
NZ (1) | NZ721009A (pl) |
PL (1) | PL3082956T3 (pl) |
PT (1) | PT3082956T (pl) |
RU (1) | RU2719934C2 (pl) |
SG (2) | SG11201604602TA (pl) |
WO (1) | WO2015092382A1 (pl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3929216A1 (en) | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
EP3868406A1 (en) * | 2015-06-24 | 2021-08-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
JP6971239B2 (ja) * | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
EP3377526A1 (en) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
MA43576A (fr) | 2015-12-16 | 2018-11-14 | Merck Sharp & Dohme | Anticorps anti-lag3 et fragments de fixation à l'antigène |
KR20180102106A (ko) * | 2016-01-08 | 2018-09-14 | 모모타로겐 가부시키가이샤 | REIC/Dkk-3 유전자 및 체크포인트 저해제를 이용한 병용 요법 |
EP3195878A1 (en) * | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
GB201601248D0 (en) * | 2016-01-22 | 2016-03-09 | Immodulon Therapeutics Ltd | Cancer therapy |
US10639368B2 (en) | 2016-05-27 | 2020-05-05 | Agenus Inc. | Anti-TIM-3 antibodies and methods of use thereof |
CA3027523A1 (en) * | 2016-06-17 | 2017-12-21 | Osaka University | Intratumoral vein-formation promoting agent |
CN110475560B (zh) * | 2016-12-15 | 2023-06-20 | 普罗基Pg500系列私人有限公司 | 组合物及其用途 |
US11077179B2 (en) | 2017-08-10 | 2021-08-03 | Epicgenetics, Inc. | Method for treating fibromyalgia and chronic fatigue syndrome |
WO2019088590A2 (ko) * | 2017-11-06 | 2019-05-09 | 서울대학교 산학협력단 | 마이코박테리움 파라고르도네의 항암 면역치료법 용도 |
AU2019293157A1 (en) * | 2018-06-25 | 2021-01-28 | Immodulon Therapeutics Limited | Cancer therapy |
GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
GB201919428D0 (en) * | 2019-12-30 | 2020-02-12 | Immodulon Therapeutics Ltd | Immunotherapeutic treatment of cancer |
CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
WO2024020436A1 (en) * | 2022-07-20 | 2024-01-25 | Immunology Diagnostics, LLC | Methods and compositions for improving immune system function |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064476A2 (en) | 1999-04-23 | 2000-11-02 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
WO2003049751A1 (en) | 2001-12-10 | 2003-06-19 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
AU2003259109A1 (en) * | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Mesothelin vaccines and model systems |
CN1859851A (zh) * | 2002-07-12 | 2006-11-08 | 约翰斯霍普金斯大学 | 间皮素疫苗与模型系统 |
US20090297540A1 (en) | 2005-10-21 | 2009-12-03 | Andrew Mellor | Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof |
GB0526033D0 (en) * | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
WO2007112316A2 (en) | 2006-03-24 | 2007-10-04 | Morton Donald L | Mycobacterial immunotherapy for cancer treatment |
WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
RU2350338C2 (ru) * | 2007-05-14 | 2009-03-27 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения поверхностного рака мочевого пузыря |
ES2616355T3 (es) * | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
US8367075B2 (en) | 2010-07-02 | 2013-02-05 | Indian Institute Of Science | Synergistic combination and method thereof |
EP2723381A4 (en) * | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS |
GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
EP2620159A1 (en) | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
BR112014018481A2 (pt) * | 2012-02-01 | 2017-07-04 | Compugen Ltd | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso |
US8617520B2 (en) * | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
WO2014064240A1 (en) * | 2012-10-26 | 2014-05-01 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
WO2014181221A2 (en) | 2013-05-08 | 2014-11-13 | Ashwin Bharadwaj | Heat sink |
GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
KR102395498B1 (ko) | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
EP3868406A1 (en) | 2015-06-24 | 2021-08-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
-
2013
- 2013-12-20 GB GBGB1322725.1A patent/GB201322725D0/en not_active Ceased
-
2014
- 2014-12-16 ES ES14827518T patent/ES2913460T3/es active Active
- 2014-12-16 EP EP14827518.3A patent/EP3082956B1/en active Active
- 2014-12-16 PL PL14827518T patent/PL3082956T3/pl unknown
- 2014-12-16 AU AU2014369510A patent/AU2014369510B2/en active Active
- 2014-12-16 CN CN202010559639.9A patent/CN111671908A/zh active Pending
- 2014-12-16 JP JP2016541474A patent/JP6858558B2/ja active Active
- 2014-12-16 IL IL246083A patent/IL246083B2/en unknown
- 2014-12-16 CN CN201480067986.2A patent/CN105979964B/zh active Active
- 2014-12-16 WO PCT/GB2014/053717 patent/WO2015092382A1/en active Application Filing
- 2014-12-16 MX MX2016007709A patent/MX2016007709A/es unknown
- 2014-12-16 NZ NZ721009A patent/NZ721009A/en unknown
- 2014-12-16 SG SG11201604602TA patent/SG11201604602TA/en unknown
- 2014-12-16 RU RU2016123370A patent/RU2719934C2/ru active
- 2014-12-16 PT PT148275183T patent/PT3082956T/pt unknown
- 2014-12-16 CA CA2932659A patent/CA2932659C/en active Active
- 2014-12-16 BR BR112016013887-2A patent/BR112016013887B1/pt active IP Right Grant
- 2014-12-16 SG SG10202111098RA patent/SG10202111098RA/en unknown
- 2014-12-16 US US15/104,890 patent/US10610577B2/en active Active
- 2014-12-16 KR KR1020167015996A patent/KR101820393B1/ko active IP Right Grant
-
2018
- 2018-08-24 US US16/112,430 patent/US10610578B2/en active Active
-
2019
- 2019-07-25 JP JP2019137010A patent/JP2019196394A/ja active Pending
-
2020
- 2020-03-10 AU AU2020201754A patent/AU2020201754B2/en active Active
- 2020-03-16 US US16/820,132 patent/US11000584B2/en active Active
- 2020-03-16 US US16/820,058 patent/US10994002B2/en active Active
- 2020-03-16 US US16/819,927 patent/US10925952B2/en active Active
-
2021
- 2021-03-31 US US17/301,331 patent/US20210213128A1/en active Pending
- 2021-03-31 US US17/301,319 patent/US20210213127A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL246083A0 (en) | A barrier inhibitor and a whole mycobacterium cell, for use in cancer treatment | |
IL256467A (en) | Block an entire cell control and microbacterium for cancer treatment | |
HK1257187B (zh) | 包含非天然胰腺β細胞的裝置以及在治療疾病如糖尿病中的用途 | |
IL272921B (en) | Combined treatment including a b-raf inhibitor and a second inhibitor | |
IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
EP2953191A4 (en) | ANION-CONDUCTIVE MATERIAL AND BATTERY | |
SG11201505858VA (en) | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease | |
HK1209799A1 (en) | A non-invasion cancer detection method and a kit for performing the same | |
RS62047B1 (sr) | Imunosupresivni agensi i njihova upotreba u terapiji | |
EP2831104A4 (en) | BIOMARKERS FOR USE IN INTEGRIN PROCESSING APPLICATIONS | |
EP2968345A4 (en) | DOUBLE MEK / PI3K INHIBITORS AND THERAPEUTIC PROCESSES USING SAME | |
EP2830719A4 (en) | MOVING METHOD IN A PHYSICALLY CONFIGURABLE SPACE AND DEVICE FOR USE WITH THE METHOD | |
EP2933327A4 (en) | CANCER CELL ISOLATION DEVICE AND METHOD FOR CANCER CELL INSULATION | |
GB201305076D0 (en) | A portable storage and activity device | |
EP2872973A4 (en) | IMPROVEMENTS IN DEVICES FOR USE WITH COMPUTERS | |
IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
HK1208735A1 (en) | Electrochromic cells and their use | |
GB201305940D0 (en) | Methods and arrays for use in the same | |
EP3017440A4 (en) | SYSTEMS AND METHOD FOR POWER MANAGEMENT IN A BEACOM | |
EP2978521A4 (en) | INCLINED BASE PLATE FOR DEHYDROGENATION REACTOR | |
GB201308753D0 (en) | Compounds and their use in therapy | |
GB201308217D0 (en) | Compounds and their use in therapy | |
SG10201704704SA (en) | Cancer cell isolation device and cancer cell isolation method |